Pursuing novel therapeutics targeting NASH

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Our most advanced clinical candidate, resmetirom, is currently being studied for the treatment of patients with NASH with significant liver fibrosis (consistent with F2/F3) and NASH with compensated cirrhosis.

Despite its significant clinical impact, there is no FDA-approved treatment for NASH.